The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

SIGi001-A-11

iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118

Gene-edited iPSC line

Stock not immediately available - enquire for details
We are currently making some changes to how EBiSC operates and because of this there is a short period of time where orders cannot be placed.

If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name SIGi001-A-11
Alternative name(s)
iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
SIGi001-A-8
(iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7)
SIGi001-A-9
(iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1)
SIGi001-A-10
(iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8)
SIGi001-A-7
(iPSC0028 MAPT P301S 2G2B7)
SIGi001-A-6
(iPSC0028 MAPT P301S 1B9C9)
SIGi001-A-3
(iPSC0028 MAPT P301L C4)
SIGi001-A-4
(iPSC0028 MAPT P301L D4)
SIGi001-A-5
(iPSC0028 MAPT P301S 1C9C4)
SIGi001-A-12
(iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570)
SIGi001-A-13
(iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11)
SIGi001-A-16
(SIGi001-A-9 Bi-Allelic MAPT HA-tag)
SIGi001-A-1
(iPSC0028 SLC17A7/GFP E3)
SIGi001-A-2
(iPSC0028 SLC17A7/GFP C3)
SIGi001-A-14
(SIGi001-A Bi-Allelic MAPT HA-tag)
SIGi001-A-15
(SIGi001-A Dox inducible NGN2)
SIGi001-A-17
(SIGi001-A-9 Dox inducible NGN2)
SIGi001-A-18
(SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5)
SIGi001-A-19
(SIGi001-A-12 Dox inducible NGN2)
Notes The parental iPSC line SIGi001-A can be sourced via Sigma as 'iPSC0028'.

Provider

Depositor Sigma-Aldrich (SIG)
Distributors
EBiSC

External Databases

hPSCreg SIGi001-A-11
BioSamples SAMEA4451118
Cellosaurus CVCL_LE50
Wikidata Q54953432

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of (not in EBiSC, see SIGi001-A in hPSCreg)

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history no
Is the medical history available upon request? no
Is clinical information available? no

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4447434

hIPSC Derivation#

General

More source cell information can be found in the parental cell line SIGi001-A in hPSCreg.

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
Unknown
Reprogramming vectors silenced?
Yes
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
VIM
Yes
MIXL1
Yes
NCAM1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
NeuroD1
Yes
PAX6
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX[17]/47,XX,+12[2]
Passage number: P37
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification#

Disease/phenotype related modifications
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Synonyms
  • PSP syndrome
Genetic modifications
MAPT (target)
Isogenic modification
17q21.31
NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-
Mutated
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Synonyms
  • cortical basal ganglionic degeneration
  • corticobasal degeneration
  • CBGD
  • cortical-basal ganglionic degeneration
  • cortico-basal ganglionic Degeneration (CBGD)
  • corticobasal syndrome
  • corticodentatonigral degeneration with neuronal achromasia
show more synonyms
Genetic modifications
MAPT (target)
Isogenic modification
17q21.31
NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-
Mutated
Genetic modifications
MAPT (target)
Isogenic modification
17q21.31
NM_016834.4 : c.[ c.727 >T; c.[741+16C>T]+[741+16C>T]]
P301S+IVS10+16 C>T; Regarding homozygosity/heterozygosity-
Mutated